Leerink Partnrs Issues Pessimistic Outlook for A Earnings

Agilent Technologies, Inc. (NYSE:A) – Equities researchers at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for shares of Agilent Technologies in a research note issued on Thursday, May 29th. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $1.37 per share for the quarter, down from their prior forecast of $1.40. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.58 per share.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, May 28th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.05. The company had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.63 billion. Agilent Technologies had a return on equity of 25.92% and a net margin of 17.59%. Agilent Technologies’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.22 EPS.

Several other research firms have also issued reports on A. Wells Fargo & Company reduced their target price on Agilent Technologies from $155.00 to $135.00 and set an “overweight” rating on the stock in a report on Thursday, April 17th. Robert W. Baird dropped their price objective on Agilent Technologies from $159.00 to $140.00 and set an “outperform” rating for the company in a research report on Thursday, May 22nd. JPMorgan Chase & Co. dropped their price objective on Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating for the company in a research report on Thursday. Jefferies Financial Group dropped their price objective on Agilent Technologies from $135.00 to $116.00 and set a “hold” rating for the company in a research report on Monday, April 21st. Finally, TD Cowen upped their price objective on Agilent Technologies to $150.00 and gave the stock a “buy” rating in a research report on Thursday. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $140.15.

Agilent Technologies Stock Performance

A opened at $111.83 on Friday. The firm has a market cap of $31.88 billion, a P/E ratio of 27.61, a price-to-earnings-growth ratio of 3.17 and a beta of 1.27. Agilent Technologies has a 52-week low of $96.43 and a 52-week high of $153.84. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.66 and a current ratio of 2.09. The business’s fifty day moving average is $108.44 and its 200-day moving average is $126.41.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 23rd. Stockholders of record on Tuesday, July 1st will be given a dividend of $0.248 per share. The ex-dividend date is Tuesday, July 1st. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.89%. Agilent Technologies’s dividend payout ratio (DPR) is 24.44%.

Insider Transactions at Agilent Technologies

In other news, Director Daniel K. Podolsky sold 1,819 shares of the firm’s stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $116.46, for a total transaction of $211,840.74. Following the completion of the transaction, the director now directly owns 35,737 shares in the company, valued at $4,161,931.02. This trade represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the transaction, the vice president now owns 21,786 shares of the company’s stock, valued at $2,657,456.28. This trade represents a 8.05% decrease in their ownership of the stock. The disclosure for this sale can be found here.

Hedge Funds Weigh In On Agilent Technologies

Several institutional investors have recently added to or reduced their stakes in the business. Global X Japan Co. Ltd. raised its position in shares of Agilent Technologies by 161.1% during the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock worth $25,000 after purchasing an additional 116 shares during the period. Redwood Park Advisors LLC acquired a new position in shares of Agilent Technologies during the fourth quarter worth approximately $27,000. Lee Danner & Bass Inc. acquired a new position in shares of Agilent Technologies during the fourth quarter worth approximately $29,000. Sunbelt Securities Inc. raised its position in shares of Agilent Technologies by 640.0% during the fourth quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company’s stock worth $30,000 after purchasing an additional 192 shares during the period. Finally, Whipplewood Advisors LLC raised its position in shares of Agilent Technologies by 286.2% during the first quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company’s stock worth $29,000 after purchasing an additional 186 shares during the period.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.